LifeScience PLUS today announced the introduction of its proven fast-acting BloodSTOP hemostatic products in global markets. The company’s patent pending hemostatic technology brings a new level of efficacy to the wound care market.
Recent Posts
- LifeScience PLUS Secures FDA 510(k) Clearance for BloodSTOP® iX Trauma Matrix for Severe Bleeding Control
- Potential New Application for BloodSTOP® iX in Neurosurgical CSF Leakage Management
- Jacobi Burn Center Highlights Clinical Success with BloodSTOP iX at ABA Annual Meeting
- LifeScience PLUS Announces Publication on Revolutionary eCMC Technology in The Journal of Burn Care and Research
- America’s Lifeblood is in Crisis: A Novel Hemostatic Dressing Provides Hope